^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Lymphocytic Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Bendamustine, rituximab + idelalisib (category 3)
    Secondary therapy:
    bendamustine
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation...Preferred regimens...Idelalisib + rituximab